scholarly journals Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer

2018 ◽  
Vol 109 (8) ◽  
pp. 2567-2575 ◽  
Author(s):  
Hiroki Osumi ◽  
Eiji Shinozaki ◽  
Tetsuo Mashima ◽  
Takeru Wakatsuki ◽  
Mitsukuni Suenaga ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Wild Type ◽  
Exon 2 ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line ◽  
Kras Exon

A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma

Lung Cancer ◽  
2020 ◽  
Vol 140 ◽  
pp. 87-92 ◽  
Author(s):  
Wei-Sen Lam ◽  
Jenette Creaney ◽  
Fred K. Chen ◽  
Wee Loong Chin ◽  
Sanjeevan Muruganandan ◽  
...  
Keyword(s):  
Phase Ii ◽  
Malignant Pleural Mesothelioma ◽  
Phase Ii Trial ◽  
Pleural Mesothelioma ◽  
Line Therapy ◽  
Third Line Therapy ◽  
Third Line
Sign in / Sign up

Export Citation Format

Share Document